FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

This study has been completed.

Study NCT00325442 Information provided by United Therapeutics

First Received: May 11, 2006 Last Updated: January 18, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	November 2010
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)